Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Blinatumomab, Venetoclax, and Inotuzumab Ozogamicin in Ph-negative B-ALL
NCT06554626Phase 2Recruiting
- Sponsor
- First Affiliated Hospital, Zhejiang University School of Medicine
- Start
- Aug 2024
- Primary completion
- Aug 2026
- Modality
- scFv Fragments, Small Molecules, Bispecific Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of blinatumomab, venetoclax, inotuzumab ozogamicin in Precursor B-cell acute lymphoblastic leukemia (B-ALL), sponsored by First Affiliated Hospital, Zhejiang University School of Medicine. Started Aug 2024; status: recruiting.
02
Drugs
blinatumomabvenetoclaxinotuzumab ozogamicin
03
Conditions
Precursor B-cell acute lymphoblastic leukemia (B-ALL)
Beyond the preview
Go deeper on NCT06554626.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06554626.